TABLE 2.
The prevalence of fear of cancer recurrence (FCR) according to Fear of Cancer Recurrence Inventory (FCRI‐SF) cut‐offs, stratified by clinical and demographic characteristics
| Survivors n (%) | Patients n (%) | |||||||
|---|---|---|---|---|---|---|---|---|
| <13 | 13–15 | 16–21 | ≥22 | <13 | 13–15 | 16–21 | ≥22 | |
| Sex | ||||||||
| Men | 1133 (54) | 271 (13) | 446 (21) | 259 (12) | 343 (51) | 103 (15) | 153 (23) | 79 (12) |
| Women | 1828 (36) | 675 (13) | 1421 (28) | 1158 (23) | 535 (37) | 222 (15) | 394 (27) | 291 (20) |
| Age groups | ||||||||
| 18–29 years | 22 (12) | 12 (6) | 54 (29) | 95 (52) | 5 (20) | 3 (13) | 4 (16) | 13 (51) |
| 30–44 years | 160 (17) | 106 (11) | 269 (29) | 398 (43) | 68 (26) | 36 (14) | 75 (28) | 85 (32) |
| 45–59 years | 770 (33) | 349 (15) | 735 (32) | 475 (20) | 288 (36) | 136 (17) | 231 (29) | 152 (19) |
| 60–74 years | 1522 (51) | 383 (13) | 684 (23) | 382 (13) | 419 (48) | 133 (15) | 207 (24) | 106 (12) |
| ≥75 years | 486 (63) | 96 (12) | 125 (16) | 67 (9) | 98 (61) | 17 (11) | 30 (19) | 15 (10) |
| Cancer type | ||||||||
| Melanoma | 89 (31) | 42 (15) | 90 (31) | 66 (23) | ||||
| Lung cancer | 56 (32) | 16 (9) | 35 (20) | 67 (38) | 35 (31) | 18 (16) | 38 (34) | 22 (20) |
| Breast cancer | 1332 (37) | 497 (14) | 1005 (28) | 778 (22) | 351 (40) | 143 (16) | 245 (28) | 140 (16) |
| Thyroid cancer | 3 (8) | 6 (15) | 8 (19) | 23 (59) | ||||
| Colorectal cancer | 335 (50) | 88 (13) | 148 (22) | 105 (16) | 203 (52) | 49 (13) | 91 (23) | 48 (12) |
| Endometrial cancer | 123 (61) | 24 (12) | 34 (17) | 22 (11) | 15 (38) | 9 (23) | 8 (21) | 8 (19) |
| Leukemia & non‐hodgkin lymphoma | 15 (20) | 10 (13) | 25 (33) | 27 (35) | ||||
| Prostate cancer | 745 (63) | 145 (12) | 201 (17) | 83 (7) | 158 (54) | 49 (17) | 57 (20) | 27 (9) |
| Other cancer types | 115 (27) | 43 (10) | 138 (32) | 133 (31) | 111 (29) | 55 (14) | 100 (26) | 114 (30) |
| Time since cancer diagnosis | ||||||||
| 0–1 year | 1053 (41) | 355 (14) | 669 (26) | 501 (19) | 487 (44) | 162 (15) | 285 (26) | 171 (15) |
| 2–5 years | 1287 (41) | 409 (13) | 817 (26) | 617 (20) | 274 (39) | 120 (17) | 175 (25) | 141 (20) |
| 6–10 years | 426 (41) | 131 (13) | 273 (26) | 204 (20) | 83 (38) | 29 (13) | 59 (27) | 46 (21) |
| >10 years | 194 (44) | 51 (11) | 109 (24) | 91 (21) | 33 (37) | 14 (15) | 28 (30) | 17 (18) |
| Continent where study was conducted | ||||||||
| Asia | 451 (49) | 116 (13) | 235 (26) | 112 (12) | 251 (40) | 87 (14) | 166 (26) | 127 (20) |
| Australia | 174 (34) | 78 (15) | 156 (30) | 111 (21) | ||||
| Europe | 1115 (41) | 380 (14) | 758 (28) | 480 (18) | 96 (46) | 27 (13) | 55 (26) | 29 (14) |
| North America | 1221 (40) | 372 (12) | 718 (24) | 713 (24) | 531 (41) | 212 (16) | 326 (25) | 215 (17) |
Note: Groups with less than 10 participants were omitted. All data were imputed, except the cancer type variable, since its imputation did not converge.